West Announces Second-Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
West Pharma (WST) Tops Q2 EPS by 34c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
July 23, 2020 6:15 AM EDTWest Pharma (NYSE: WST) reported Q2 EPS of $1.25, $0.34 better than the analyst estimate of $0.91. Revenue for the quarter came in at $527.2 million versus the consensus estimate of $496.09 million.
Second-Quarter 2020 Summary (comparisons to prior-year period)
Net sales of $527.2 million grew 12.2%; organic sales growth was 14.3%.Reported-diluted EPS of $1.21 increased 38%.Adjusted-diluted EPS of $1.25 increased 40%.Company is raising full-year 2020 net sales guidance to a new range of between $2.035 billion and $2.055 billion.Company is raising full-year 2020 adjusted-diluted EPS guidance to a new range of between $4.15 and $4.25."Adjusted-diluted EPS"... More
